FAQ

agalsidase beta

Known as: agalsidase beta [Chemical/Ingredient] 
 

Topic mentions per year

Topic mentions per year

2005-2018
01220052018

Related topics

Related topics

6 relations
ALPHA-D-GALACTOSIDASE ENZYMEAlpha-glucosidaseDrug AllergyFabry Disease

Narrower (1)

Fabrazyme

Broader (1)

Isoenzymes

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
agalsidase beta
Drug Allergy
Isoenzymes
Fabry Disease
Alpha-glucosidase
ALPHA-D-GALACTOSIDASE ENZYME

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
BACKGROUND Two recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2017
2017
Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
There are currently two available enzyme replacement therapies for Fabry disease and little information regarding efficacy and… (More)
Is this relevant?
Review
2017
Review
2017
Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature
Background:In 2009, the agalsidase beta shortage resulted in switching to agalsidase alfa treatment for many Fabry disease… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2017
2017
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.
Fabry disease, an X-linked inherited lysosomal storage disorder, is caused by mutations in the gene encoding α-galactosidase, GLA… (More)
Is this relevant?
2016
2016
Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry.
BACKGROUND Fabry disease, an X-linked lysosomal storage disorder, causes intracellular accumulation of glycosphingolipids leading… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2014
Review
2014
Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
BACKGROUND Fabry disease is an X-linked inherited lysosomal storage disease that can be treated with the enzymes of agalsidase… (More)
Is this relevant?
2014
2014
First-in-human study with new recombinant agalsidase beta (ISU303) in healthy subjects.
ISU303 is a new recombinant agalsidase beta (Agal) enzyme replacement therapy under investigation for Fabry disease, caused by a… (More)
Is this relevant?
2011
2011
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy
Anderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is frequently… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2010
2010
Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report.
No reproductive studies have been performed with enzyme replacement therapy (ERT) for Fabry disease (FD, OMIM 301500), a… (More)
Is this relevant?
2005
2005
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Gastrointestinal symptoms are often an early and prominent manifestation of Fabry disease, an X-linked inborn error of metabolism… (More)
Is this relevant?